hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06274008, orgStudyIdInfo id: 230110, briefTitle: Exparel vs. ACB With Bupivacaine for ACL Reconstruction, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-12, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Children's Hospital of Orange County, class: OTHER, descriptionModule briefSummary: Opioid misuse and addiction among children and adolescents is an increasingly concerning problem. Post-surgical opioid prescriptions for commonly performed surgeries such as anterior cruciate ligament reconstruction (ACLR) increase opioid exposure in young athletes. The purpose of the current study is to determine if extended-release Bupivacaine Liposome Injectable Suspension (Exparel) is effective in decreasing at home narcotic consumption compared to standard Bupivacaine Adductor Canal Block for Anterior Cruciate Ligament (ACL) reconstruction/reconstruction for the surgical treatment of adolescents with ACL tears and concomitant pathology i.e. meniscus / cartilage injury/tear., conditionsModule conditions: ACL Tear, conditions: Opioid Misuse, conditions: Pain, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 96, type: ESTIMATED, armsInterventionsModule interventions name: Exparel, outcomesModule primaryOutcomes measure: At-home narcotic consumption by the patients as measured by the medication form completed by parents post discharge, secondaryOutcomes measure: Postoperative pain level of child, secondaryOutcomes measure: Functional disability of child, secondaryOutcomes measure: Parent and child anxiety, secondaryOutcomes measure: Child pain, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: CHOC Children's Hospital, status: RECRUITING, city: Orange, state: California, zip: 92868, country: United States, contacts name: Haydee Cortes, role: CONTACT, phone: 714-456-2837, email: haydee.cortes@choc.org, contacts name: Kiran Athreya, role: CONTACT, phone: 9493064857, email: kiran.athreya@choc.org, contacts name: John Schlechter, DO, role: PRINCIPAL_INVESTIGATOR, contacts name: Zeev N. Kain, MD, role: SUB_INVESTIGATOR, geoPoint lat: 33.78779, lon: -117.85311, hasResults: False
protocolSection identificationModule nctId: NCT06273995, orgStudyIdInfo id: H-54233, briefTitle: Telehealth Behavioral Activation for Teens, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2029-03-01, completionDateStruct date: 2029-12-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Baylor College of Medicine, class: OTHER, collaborators name: University of Texas, descriptionModule briefSummary: Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depressed youth. Additionally, it has been shown as a promising intervention that can be conducted in a brief, virtual format and can be effectively implemented by both trained clinicians and trained, non-licensed interventionists. This project will provide Behavioral Activation for youth (12-17) experiencing depression or suicidal ideation who are currently enrolled in the Youth Depression Suicide Network study in Texas., conditionsModule conditions: Depression, conditions: Suicide and Self-harm, conditions: Depression in Adolescence, conditions: Depression Mild, conditions: Depression Moderate, conditions: Depression Severe, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single group, open-label behavioral activation, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Behavioral Activation, outcomesModule primaryOutcomes measure: Patient Health Questionnaire 9-modified for adolescents (PHQ-A), primaryOutcomes measure: Behavioral Activation for Depression-Short Form (BAD-SF), primaryOutcomes measure: Dimensional Anhedonia Rating Scale (DARS), secondaryOutcomes measure: Strengths and Difficulties Questionnaire (SDQ), secondaryOutcomes measure: Duke Social Support Index (DSSI), eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Baylor College of Medicine, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Eric Storch, Ph.D., role: CONTACT, phone: 713-798-3080, email: eric.storch@bcm.edu, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06273982, orgStudyIdInfo id: 1R01MH131698, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01MH131698, briefTitle: Behavioral Telehealth in Low-resource Primary Care Settings for Anxiety and Depression in Youth, acronym: STEP-UP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2028-05-31, completionDateStruct date: 2028-05-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: San Diego State University, class: OTHER, collaborators name: Kaiser Permanente, collaborators name: OCHIN, Inc., descriptionModule briefSummary: The goal of this clinical trial is to test a brief, behavioral telehealth treatment program (STEP-UP) for depression and anxiety in youths (age 8-16 years old). Youths and families will be recruited through participating community health centers and will be randomly assigned to either: (a) receive STEP-UP care from providers at their health center or (b) be referred to care from local community mental health clinicians. Youth and families will be interviewed before treatment starts, 16 weeks later, and 24 weeks later to assess how youth are feeling. The main question the study aims to answer is whether STEP-UP improves youths functioning in daily life, anxiety symptoms, and depression symptoms. Researchers will compare STEP-UP to referral to community treatment-as-usual mental health services to see if STEP-UP is more effective., conditionsModule conditions: Depression, Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 220, type: ESTIMATED, armsInterventionsModule interventions name: STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression), interventions name: ARC (assisted referral to community care), outcomesModule primaryOutcomes measure: Children's Global Assessment Scale (CGAS), primaryOutcomes measure: Pediatric Anxiety Rating Scale (PARS), primaryOutcomes measure: Children's Depression Rating Scale -- Revised (CDRS-R), eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 16 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06273969, orgStudyIdInfo id: PK20240105- 001, briefTitle: Ultrasonographic Evaluation of Osteopathic Manipulation for Thoracic Outlet Syndrome, acronym: TOS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-04-24, completionDateStruct date: 2024-04-24, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: A.T. Still University of Health Sciences, class: OTHER, descriptionModule briefSummary: The purpose of the study is to develop a protocol to assess blood flow in the upper limb vasculature before and after osteopathic manipulative treatment (OMT) using Pulsed-wave Doppler ultrasonography (US). We will assess the subclavian artery and vein at two locations (above and below the clavicle) and the brachial artery and vein (within the axilla) to determine the reproducibility of the blood flow findings at each location and the impact of OMT on the blood flow. Additionally we will qualitatively assess morphological changes of the brachial plexus before and after OMT with US., conditionsModule conditions: Thoracic Outlet Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Twelve consented male and/or female volunteers between the ages of 18 and 65 with intermittent tingling and/or numbness in one or both hands that has occurred with two weeks of the start date of the study will be evaluated using pulsed-wave doppler ultrasonography (US) and then treated with osteopathic manipulative treatment (OMT).US examination of the thoracic outlet will be performed using a Mindray-6 ultrasound machine and will include 4 views/positions with the subject in a seated position.The following intervention will consist of four osteopathic manipulation techniques (OMT) being performed that target the somatic dysfunctions associated with TOS. These techniques include: 1) Direct Thoracic Inlet Myofascial Release (TIMFR); 2) Direct Muscle Energy for the Scalene Muscles; 3) Direct Muscle Energy for the Pectoralis Muscles; and 4) Supraclavicular Fascial Release., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Osteopathic Manipulative Treatment (OMT), outcomesModule primaryOutcomes measure: Blood flow changes in the upper extremity., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06273956, orgStudyIdInfo id: bleeding scores in ItP, briefTitle: Explore the Relationship Between Platelet Count and Bleeding Score in ITP, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-04-10, primaryCompletionDateStruct date: 2025-10-10, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Assessment of bleeding scores in immune thrombocytopenia purpuria to explore the relationship between platelet count and bleeding score in immune thrombocytopenia purpura (ITP) and compare the clinical practicability of bleeding grading systems with adult patients with ITP., conditionsModule conditions: ITP - Immune Thrombocytopenia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: explore the relationship between platelet count and bleeding assessment systems (ITP Bleeding Assessment Tool (ITP -BAT) and ITP Bleeding Scale (IBLS) in Patients with ITP to measure severity of bleeding, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Aml Sayed Hamed, status: RECRUITING, city: Assiut, country: Egypt, contacts name: Rania Mohammed Mahmoud Hafez, professor, role: CONTACT, phone: +201000019198, email: raniahafez@aun.edu.eg, contacts name: Yousreyia Abdel Rahman Ahmed, professor, role: CONTACT, phone: +201223971307, email: dr_yousryeia@yahoo.com, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06273930, orgStudyIdInfo id: AFID, briefTitle: Reduction of Dentine Hypersensitivity After Use of Different Dentifrices, acronym: Dentrifices, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-10-15, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Armed Forces Institute of Dentistry, Pakistan, class: OTHER, descriptionModule briefSummary: To assess the impact of the use of 5% Calcium Sodium Phosphosilicate or 8% Arginine dentifrices on dentinal hypersensitivity following non-surgical periodontal therapy in patients with periodontitis., conditionsModule conditions: Sensitivity, Tooth, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 87, type: ESTIMATED, armsInterventionsModule interventions name: 5% CALCIUM SODIUM PHOSPHOSILICATE, interventions name: 8% Arginine, outcomesModule primaryOutcomes measure: To assess the impact on Dentinal hypersensitivity following the use of 5% CSPS or 8% Arginine following non-surgical periodontal therapy in patients with Periodontitis by VAS., primaryOutcomes measure: To assess the impact on Dentinal hypersensitivity following the use of 5% CSPS or 8% Arginine following non-surgical periodontal therapy in patients with Periodontitis by Schiff scale., eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AFID, status: RECRUITING, city: Rawalpindi, country: Pakistan, contacts name: Muhammad J Iqbal, role: CONTACT, geoPoint lat: 33.6007, lon: 73.0679, hasResults: False
protocolSection identificationModule nctId: NCT06273891, orgStudyIdInfo id: INOVA-2023-58, briefTitle: Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes, acronym: PRACET, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-10-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Inova Fairfax Hospital, class: OTHER, descriptionModule briefSummary: The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM., conditionsModule conditions: Premature Rupture of Membrane, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Erythromycin, interventions name: Azithromycin, outcomesModule primaryOutcomes measure: Latency period, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Inova Fairfax Medical Campus, status: RECRUITING, city: Falls Church, state: Virginia, zip: 22042, country: United States, contacts name: Ellen M Murrin, DO, role: CONTACT, phone: 703-776-6040, email: ellen.murrin@inova.org, contacts name: Antonio Saad, MD, MBA, role: PRINCIPAL_INVESTIGATOR, contacts name: Ellen M Murrin, DO, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.88233, lon: -77.17109, hasResults: False
protocolSection identificationModule nctId: NCT06273878, orgStudyIdInfo id: RS1439/20, briefTitle: From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-15, primaryCompletionDateStruct date: 2025-01-15, completionDateStruct date: 2025-01-15, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Regina Elena Cancer Institute, class: OTHER, collaborators name: Università degli Studi dell'Insubria, descriptionModule briefSummary: Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients., conditionsModule conditions: Endometrial Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 80, type: ESTIMATED, outcomesModule primaryOutcomes measure: Validate the differential expression of LOX-1 and NALP3 receptors., secondaryOutcomes measure: Characterize phenotypic alterations., secondaryOutcomes measure: Evaluate the predictive and/or prognostic value., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Institute - IFO -, status: RECRUITING, city: Rome, state: RM, zip: 00144, country: Italy, contacts name: Benito Chiofalo, Doctor, role: CONTACT, phone: ND, email: benito.chiofalo@ifo.gov.it, contacts name: Valentina Bruno, Doctor, role: CONTACT, phone: ND, email: valentina.bruno@ifo.gov.it, geoPoint lat: 41.89193, lon: 12.51133, locations facility: "Regina Elena" National Cancer Institute, status: RECRUITING, city: Rome, zip: 00144, country: Italy, contacts name: Benito Chiofalo, Doctor, role: CONTACT, phone: ND, email: benito.chiofalo@ifo.it, contacts name: Valentina Bruno, Doctor, role: CONTACT, phone: ND, email: valentina.bruno@ifo.gov.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06273852, orgStudyIdInfo id: PBL-0405-01, briefTitle: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Pure Biologics S.A., class: INDUSTRY, collaborators name: Presage Biosciences, descriptionModule briefSummary: This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device., conditionsModule conditions: Head and Neck Squamous Cell Carcinoma, conditions: Soft Tissue Sarcoma Adult, conditions: Triple Negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This substudy is not blinded., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: PBA-0405, outcomesModule primaryOutcomes measure: Quantification of Cell Death and Immune Cell Biomarkers by immuno-histochemistry (IHC) and In-Situ Hybridization (ISH), secondaryOutcomes measure: Number of Patients with Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06273839, orgStudyIdInfo id: B3461114, briefTitle: A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2024-05-27, completionDateStruct date: 2024-05-27, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this clinical trial is to compare the amount of tafamidis in the blood of healthy adult participants after taking three different forms of tafamidis by mouth., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: Tafamidis 61 mg free acid tablet (Test 1), interventions name: Tafamidis 70 mg free acid tablet (Test 1), interventions name: Tafamidis 61 mg free acid capsule (Reference), outcomesModule primaryOutcomes measure: Area under the concentration-time curve (AUCinf), primaryOutcomes measure: Maximum observed plasma concentration (Cmax), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pfizer Clinical Research Unit - Brussels, city: Brussels, state: Bruxelles-capitale, Région DE, zip: B-1070, country: Belgium, geoPoint lat: 50.85045, lon: 4.34878, hasResults: False